Alnylam Pharmace. sell fenjal
Start price
24.06.24
/
50%
€210.70
Target price
24.06.25
-
Performance (%)
8.16%
End price
01.07.24
€227.90
Summary
This prediction ended on 01.07.24 with a price of €227.90. The SELL prediction by fenjal shows the price for Alnylam Pharmace. slightly increased by 8.16% during the runtime of the prediction. fenjal has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 5.040% | 5.040% | -46.727% |
| iShares Core DAX® | 0.881% | 5.632% | 8.477% |
| iShares Nasdaq 100 | 2.390% | 1.571% | 28.412% |
| iShares Nikkei 225® | 4.269% | 2.521% | 50.984% |
| iShares S&P 500 | 1.171% | 2.545% | 23.603% |
Comments by fenjal for this prediction
In the thread Alnylam Pharmace. diskutieren
Sell Alnylam Pharmace.